Home Patent Forecast® Sectors Log In   Contact  
How it works Patent Forecast® Sectors Insights
Menu

Oral Cannabinoid Patent Race

Z-ARCHIVE-Cannabis Patent Forecast®

October 29, 2020

Just this past week, six (6) patent applications (U.S. Patent Pub. Nos. 20200330339, '378, '423, '424, '425, & '602) were published in regards to oral cannabis compositions by five different companies: APIRx Pharmaceutical USA, LLC, ICD Pharma Ltd., MedCan Pharma A/S, PharmaCytics B.V., and NordicCan A/S

Cannabis is gaining popularity quickly with more people finding ways to incorporate it into their lifestyles. Not everyone will be willing to smoke dry cannabis products, giving way to the development of oral solutions - especially for the medical cannabis industry. 

Of the five assignees, APIRx Pharmaceuticals USA is the most active in cannabis composition filings right behind cannabis giants GW Pharmaceuticals plc and MannKind Corporation. The other four assignees will need to increase their filing activity if they want to become a leader in the space - or they could be like cannabis giant Aurora Cannabis Inc

Explore the vast portfolio of GW Pharmaceuticals and MannKind Corporation using the Magic Number® Cannabis Patent Forecast® to see what these five companies are up against. Start your free trial today!


Relevant Patent Documents

Application US20200330423  

Application US20200330424  

Application US20200330339  

Application US20200330602  

Application US20200330425  

Application US20200330378  


View Patent Forecast®

Cannabis is now legally being used to treat a wide variety of medical conditions, including chronic pain, alcoholism, anxiety, nausea (from chemotherapy) and epilepsy.

Z-ARCHIVE-Cannabis   Patent Forecast®

View Patent Forecast® Top Corporations News and Insights Data Visualization

Cannabis is now legally being used to treat a wide variety of medical conditions, including chronic pain, alcoholism, anxiety, nausea (from chemotherapy) and epilepsy.



301